Gen 2 Device Development - KnowU
The KnowU, a wearable noninvasive continuous glucose monitoring device, was announced on February 27. It is significantly smaller, lighter, includes onboard computing power, and built-in machine learning capabilities.
Positive Clinical Trial Results
An internal trial with more than 30 participants showed a mean absolute relative difference (MARD) of 11.1%, indicating promising accuracy of the glucose monitoring technology.
Significant Intellectual Property Growth
Over 300 patents issued, pending, and in process, reflecting innovation in radio frequency spectroscopy technology.
Funding Agreement Secured
Entered into a funding agreement for an investment of up to $12 million with Lind Global Fund II LP to accelerate development.
Engagement with Diabetes Community
Participated in significant conferences like ATTD, where the KnowU was displayed, and received an emerging technology grant as an outstanding startup.
Reduction in Operating Loss
Operating loss decreased by 1.7% from $4.81 million in Q2 fiscal 2023 to $4.73 million in Q2 fiscal 2024.